Abstract:CSF abnormalities and a neuroinflammatory pathophysiology have been discussed for affective and non-affective psychosis for more than 30-years. Recent studies pointed towards a specific phenotype of autoimmune-antibody mediated psychosis, but evidence is still sparse. Especially CSF data investigating autoimmune antibodies in large-scale CSF cohorts of affective and non-affective psychoses are lacking. We analyzed a retrospective naturalistic cohort of 592 patients with A) schizophrenia-spectrum disorders (N = 330) or B) depressive disorders (N = 262) who underwent a lumbar puncture as part of the clinical routine in the Department of Psychiatry and Psychotherapy at the Ludwig-Maximilians University Munich between July 2012 and May 2017. We used a predefined systematic algorithm for the database search in the clinical documentation system and data was extracted by TO and AG. The study was approved by the local ethics committee. We identified 592 patients with standard CSF parameters. Schizophrenia spectrum patients did not differ from depressive patients with regard to the white blood cell count (cells/µl) (p = 0.774) or albumin quotient (p = 0.663). The general prevalence of oligoclonal bands did not differ between groups (schizophrenia: 37.0%, depression: 37.8%; p = 0.838). However, schizophrenia patients showed higher frequencies for intrathecal oligoclonal bands (32% of all oligoclonal bands) compared to depressive patients (19.1% of all oligoclonal bands. (p = 0.034). 124 schizophrenia-spectrum patients (54 first-episode patients) received CSF analyses for neural antibodies. None of the patients showed positive CSF results in any of the tested autoimmune-encephalitis panel (NMDA(N=119), AMPA-1(N=114), AMPA-2(N=114), CASPR(N=111), LGI-1(N=110) and GABA-B(N=112)-Antibodies) in CSF. The results for the intracellular onconeuronal and synaptic antibodies were also negative (Amphyphysin(N=93), Yo(N=58), Hu(N=94), Ri(N=94), CV2(N=93), Ma1(N=93) and Ma2(N=93)-Antibodies). Three of these patients with negative CSF titers did have low-titer neuronal antibodies in serum: CASPR-2-AB: 1:10, CASPR-2-AB: 1:50, Yo-AB: low band-intensity. 36 depression patients were also tested for autoimmune antibodies and again no positive reports could be identified in CSF. This is the first analyses of autoimmune antibodies in first-episode and recurrent schizophrenia and depressive mood disorder showing no positive CSF titers. However, schizophrenia patients have a higher prevalence of intrathecal oligoclonal bands compared to affective patients pointing towards more immunological disturbances in this population. The here presented analyses are exploratory and need to undergo confirmatory analyses and quality control.

The study of serum levels of anti-brain antibody and plasma levels of S100b protein in schizophrenic

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment.

Increased serum S100B protein in long-term antipsychotic medication chronic patients with schizophrenia

Expression of S100B Protein Levels in Serum and Cerebrospinal Fluid with Different Forms of Neuropsychiatric Systemic Lupus Erythematosus.

Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers

Increased serum S100B protein in the first-episode medication-free patients with schizophrenia

High S100B Levels in Cerebrospinal Fluid and Peripheral Blood of Patients with Acute Basal Ganglial Hemorrhage Are Associated with Poor Outcome.

Correlation of serum S100B protein and human anti-brain tissue antibody levels with cognitive function in patients with Alzheimer's disease

Serum S100B protein and white matter changes in schizophrenia before and after medication

Serum Levels of Oxidants and Protein S100B Were Associated in the First-Episode Drug Naïve Patients with Schizophrenia

Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia

A control study of relationship between clinical features and serum levels of brain derivedneurotrophic factors in chronic schizophrenic patients

Correlations between Immunoinflammatory Factor Levels and Cognitive Functions and Brain Structural Magnetic Resonance Imaging Features among Patients with Primary Schizophrenia

A comparative study on serum S100B protein levels between chronic schizophrenic patients with and without tardive dyskinesia.

F107. CSF ABNORMALITIES IN SCHIZOPHRENIA AND DEPRESSION: PRELIMINARY RESULTS FROM A LARGE SCALE COHORT

Ndt_a_218483 191..199

Increased S100B Serum Levels in Schizophrenic Patients with Tardive Dyskinesia: Association with Dyskinetic Movements

Serologic evaluation of cytomegalovirus (CMV), Toxoplasma gondii and Brucella in schizophrenia patients

Elevated Interleukin-2, Interleukin-6 and Interleukin-8 Serum Levels in Neuroleptic-Free Schizophrenia: Association with Psychopathology

Relationship between serum levels of BDNF,IL-6 and Hcy with cognitive function impairment in patients with first episode schizophrenia

Correlation of serum S100 B protein level with cognitive function in bipolar disorder typeⅠpatients